In the latest session, Nektar Therapeutics (NASDAQ: NKTR) closed at $1.49 down -5.10% from its previous closing price of $1.57. On the day, 1589281 shares were traded.
Ratios:
For a deeper understanding of Nektar Therapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.14 and its Current Ratio is at 6.45. In the meantime, Its Debt-to-Equity ratio is 1.76 whereas as Long-Term Debt/Eq ratio is at 1.61.
Jefferies Upgraded its Underperform to Hold on May 10, 2023, whereas the target price for the stock was revised from $1.50 to $1.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 20 ’24 when ROBIN HOWARD W sold 20,033 shares for $0.68 per share. The transaction valued at 13,622 led to the insider holds 879,889 shares of the business.
Zalevsky Jonathan sold 9,014 shares of NKTR for $6,130 on Feb 20 ’24. The Chief R&D Officer now owns 265,025 shares after completing the transaction at $0.68 per share. On Feb 20 ’24, another insider, Wilson Mark Andrew, who serves as the Chief Legal Officer of the company, sold 7,606 shares for $0.68 each. As a result, the insider received 5,172 and left with 236,674 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.04 while its Price-to-Book (P/B) ratio in mrq is 2.18.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.75, while it has fallen to a 52-week low of $0.41.
Shares Statistics:
A total of 191.38M shares are outstanding, with a floating share count of 177.94M. Insiders hold about 3.09% of the company’s shares, while institutions hold 65.27% stake in the company.
